1. What the law is
Arizona has a psilocybin prescription law that does nothing yet. SB 1555, Chapter 231 of 2025, signed June 27, 2025, added A.R.S. 36-2517.02, which would let an FDA-approved crystalline polymorph psilocybin be prescribed in the state, but only if it is also rescheduled out of Schedule I on or before January 1, 2031. Neither step has happened, so the section sits dormant. The research money is real: the FY2026 budget carries a $5 million ibogaine study appropriation. Psilocybin is otherwise a controlled substance here, with no access program.
Two tracks run in parallel here and neither one opens a door. The money came first: the state budget signed in May 2023 put $5 million into clinical trials of whole-mushroom psilocybin, naming post-traumatic stress disorder, depression and anxiety among the target conditions, and the trial began enrolling first responders and military veterans at the Scottsdale Research Institute in late 2025. The FY2026 budget added a further $5 million for an ibogaine clinical research grant. The law is SB 1555, Chapter 231, signed June 27, 2025. It would let Arizona practitioners prescribe psilocybin in FDA-approved crystalline polymorph form, but only if the federal Drug Enforcement Administration first moves the substance out of Schedule I by January 1, 2031. Until that happens the statute authorizes nothing, and if the deadline passes without federal action the authorization never takes effect. Psilocybin is otherwise a controlled substance in Arizona, with no decriminalization measure, therapeutic access program or licensing framework in effect.
Arizona is the clearest example of the research-and-trigger-law model: fund clinical evidence, pre-commit to federal outcomes, and build no state access system of the kind Oregon and Colorado operate. SB 1555 stakes medical access on federal rescheduling rather than state licensing. The approach parallels Texas, which has financed psychedelic research at larger scale but has not enacted a prescription trigger. Near-term prospects run through the legislature: the 2026 bills on MDMA trials, veteran psilocybin therapy, and additional ibogaine research stalled amid the April 2026 budget standoff and veto moratorium, leaving research appropriations as the state's only active psychedelic policy track.
2. Trials in Arizona
Interventional psilocybin trials with at least one site in Arizona, as their sponsors filed them with ClinicalTrials.gov, EU CTIS and ISRCTN. Each row links to the registry record, which sets out who may take part.
Recruiting or opening counts trials recruiting now, not yet recruiting, or enrolling by invitation. Closed counts trials terminated, suspended, withdrawn or left unverified by their sponsors.
| Registry ID | Trial | Phase | Sponsor | Status | Start date |
|---|---|---|---|---|---|
| NCT07347405 | Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. (opens in new tab)Recruiting at The Clinical and Translational Sciences Research Center, Tucson | Phase Phase 1 | Sponsor Francisco A Moreno | Status Recruiting | Start date |
| NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting at Lighthouse Psychiatry, Gilbert | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Start date |
| NCT06992999 | Psilocybin for Treatment of OCD-2 (opens in new tab)Site at University of Arizona-Tucson | Phase Phase 1/2 | Sponsor Francisco A Moreno | Status Not yet recruiting | Start date |
| NCT06605105 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (opens in new tab)Site at Scottsdale Research Institute, Phoenix | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Enrolling by invitation | Start date |
| NCT07275970 | Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD (opens in new tab)Site at Scottsdale Research Institute, Scottsdale | Phase Phase 1 | Sponsor Scottsdale Research Institute | Status Active, not recruiting | Start date |
| NCT06564818 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Sites in Phoenix and Tucson | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Active, not recruiting | Start date |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (opens in new tab)Site at Lighthouse Psychiatry Scottsdale, Gilbert | Phase Phase 3 | Sponsor COMPASS Pathways | Status Active, not recruiting | Start date |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (opens in new tab)Site at University of Arizona College of Medicine - Tuscon | Phase Phase 3 | Sponsor COMPASS Pathways | Status Completed | Start date |
| NCT03300947 | Psilocybin for Treatment of Obsessive Compulsive Disorder (opens in new tab)Site at University of Arizona, Tucson | Phase Phase 1 | Sponsor University of Arizona | Status Completed | Start date |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
3. History
The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.
Gov. Katie Hobbs signs the FY2024 state budget, which appropriates $5 million for clinical trials of whole-mushroom psilocybin targeting PTSD, depression, and anxiety, and establishes a psilocybin research advisory council.
SB 1555 (Chapter 231) signed April 22: a trigger law permitting FDA-approved crystalline polymorph psilocybin to be prescribed in Arizona only if the DEA reschedules psilocybin out of Schedule I by January 1, 2031. It has no current operative effect.
FY2026 state budget enacted with a $5 million appropriation, advanced through the HB 2871 push, for a grant funding clinical research on ibogaine for neurological conditions including traumatic brain injury and PTSD.
The state-funded whole-mushroom psilocybin PTSD trial launches at the Scottsdale Research Institute, enrolling police officers, firefighters, and military veterans under medical supervision.
2026 session bills (SB 1542, $10 million for MDMA trials for veterans and first responders; SB 1060, psilocybin therapy for veterans; HB 2486, ibogaine research) stall without passage as Gov. Hobbs imposes a blanket veto moratorium during the budget standoff.
4. Proposed laws
Proposals that are not yet law and would change this entry if adopted.
SB 1542 (2026) would extend workers' compensation coverage to one course of midomafetamine treatment for firefighters and certified peace officers diagnosed with post-traumatic stress disorder, and would amend A.R.S. 36-2511 as amended by Laws 2025, chapter 231; note that 36-2511 is the nomenclature section, and the conditional psilocybin prescription provision sits at A.R.S. 36-2517.02, added by the same chapter. azleg.gov holds no Senate-engrossed version of the bill, so it did not pass the Senate. Two measures previously recorded here are unrelated legislation: SB 1060 (2026) concerns voter registration and HB 2486 (2026) concerns distressed residential property, per their introduced texts at azleg.gov, verified 16 August 2026. The wider 2026 session was not separately enumerated for other psilocybin bills, so nothing is asserted about bills beyond these three.
5. Common questions
Is psilocybin legal in Arizona?
Psilocybin has mixed legal status in Arizona.
Are magic mushrooms ("shrooms") legal in Arizona?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin, and this entry states the law on psilocybin itself, which some laws treat separately from the fungus. Psilocybin has mixed legal status in Arizona.
Read the law
SB 1555 (2025, Chapter 231), approved by the Governor and filed with the Secretary of State on June 27, 2025: a conditional trigger law adding A.R.S. 36-2517.02, under which a pharmaceutical composition of crystalline polymorph psilocybin that is approved by the FDA and rescheduled by the DEA to a schedule other than Schedule I is a controlled substance for the purposes of the chapter and may be prescribed in this state. Under section 5 of the chapter that provision does not become effective unless the approval and a federal interim final rule under 21 U.S.C. 811(j) are in place on or before January 1, 2031. FY2026 state budget (via HB 2871 push): $5M for ibogaine clinical research. Earlier $5M whole-mushroom psilocybin PTSD clinical trial funding (2023).1
Sources
This entry's status is checked against the primary sources below, and the methodology explains how each entry is graded for confidence.
- 1.azleg.gov (opens in new tab) · azleg.gov
- 2.Marijuana Moment.Marijuana Moment (opens in new tab) · marijuanamoment.net
This entry is for information only and is not legal or medical advice. Laws change, and enforcement can differ from the letter of the law, so check the current position against the primary sources above before relying on it.
Changes to this record
3 changes on file, the latest on . Show allHide
Every change we have made to this record, dated, corrections included. Nothing changes silently.
Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.
Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.
Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.
Psilocybin Media Group. "Arizona: psilocybin legal status." The Psilocybin Record, accession US-AZ-001, version of 23 Aug 2026. https://psilocybinlegalization.com/record/arizona